This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
LifeSpan Biosciences
product type :
ELISA/assay
product name :
Human PROKR2/Prokineticin Receptor 2 (Sandwich ELISA) ELISA Kit - LS-F36582
catalog :
LS-F36582
product information
ElisaKitId :
36582
ElisaKitType :
Sandwich
CatalogNumber :
LS-F36582
TargetSpecies :
Human
Product Name :
Human PROKR2/Prokineticin Receptor 2 (Sandwich ELISA) ELISA Kit - LS-F36582
SampleType :
Plasma, Serum, Tissue Homogenates
MeasurementType :
Quantitative
FormatType :
96-Well Strip Plate
DetectionType :
Colorimetric - 450nm (TMB)
DetectionRange :
0.313 - 20 ng/ml
RecommendedStorage :
Store at 4°C. Stable for 6 months.
Precision :
Intra-Assay: CV<8% Inter-Assay: CV<10%
Gene :
PROKR2/Prokineticin Receptor 2
StandardGeneSymbol :
PROKR2
gene family :
GPCR
Reactivity :
Human
Synonyms :
PROKR2, DJ680N4.3, GPCR73B, HH3, GPR73b, KAL3, GPRg2, Prokineticin receptor 2, PK-R2, PKR2, GPR73L1
SalesRegion :
Worldwide
company information
LifeSpan Biosciences
2401 Fourth Avenue, Suite 900
Seattle, WA 98121
Seattle, WA 98121
CustomerSupport@lsbio.com
https://www.lsbio.com1-206-464-1554
headquarters: USA
Since 1995, LifeSpan has been the industry leader in molecular pathology, specializing in the localization of proteins in normal and diseased tissues, both human and non-human. We offer more than 74,000 antibodies, custom designed immunohistochemistry (IHC) studies, immediately available human tissue IHC profiles for more than 500 proteins, and histology and pathology services. Our bank of 2 million specimens is available to support our customers' contract research studies and contains frozen and formalin-fixed (FFPE) normal and diseased tissues. Our contract services are comprehensive; they include study design, antibody sourcing and characterization, tissue sourcing and validation, immunolabeling, trouble shooting, and interpretation of the results by a LifeSpan pathologist.
questions and comments